The inclusion of neffy on Express Scripts’ Commercial National Formularies significantly expands access to millions of commercially insured patients, improving availability of life-saving allergy ...
Company's immunology franchise demonstrates strong market momentum with preferred status under one of the largest pharmacy benefit managers in the nation RALEIGH, N.C., Dec. 1, 2025 /PRNewswire/ -- ...
Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 ...
HERCESSI™ becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...
Company's immunology franchise demonstrates strong market momentum with preferred status under one of the largest pharmacy benefit managers in the nation IMULDOSA, a biosimilar to STELARA® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results